For anti-PD-1 therapies in OSCC prevention, we should mention that in September 2022, the Hanna team published their latest results on the therapeutic effect of nivolumab (an anti-PD-1 antibody) in high-risk OLK, with a favorable overall cancer-free-survival of 37%48. This evidence concerns the gene PDCD1 and cancer.